Trial Profile
Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 29 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2026.
- 03 Jul 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2026.